The mediator RIPK3 activates CaMKII (phosphorylation/oxidation) to drive cardiomyocyte necroptosis, whereas MyD88 deficiency prevents oxidised CaMKII and post–MI hypertrophy/inflammation. Here, MYD88 is linked to myocardial infarction.